| A plasmonic gold nanostar theranostic probe for in vivo tumor imaging and photothermal therapy Y Liu, JR Ashton, EJ Moding, H Yuan, JK Register, AM Fales, J Choi, ... Theranostics 5 (9), 946, 2015 | 314 | 2015 |
| Astatine-211-labeled radiotherapeutics an emerging approach to targeted alpha-particle radiotherapy MR Zalutsky, G Vaidyanathan Current pharmaceutical design 6 (14), 1433-1455, 2000 | 269 | 2000 |
| Labeling proteins with fluorine-18 using N-succinimidyl 4-[18F] fluorobenzoate G Vaidyanathan, MR Zalutsky International journal of radiation applications and instrumentation. Part B …, 1992 | 186 | 1992 |
| Synthesis of N-succinimidyl 4-[18F]fluorobenzoate, an agent for labeling proteins and peptides with 18F G Vaidyanathan, MR Zalutsky Nature protocols 1 (4), 1655-1661, 2006 | 179 | 2006 |
| Targeted α-particle radiotherapy with 211At-labeled monoclonal antibodies MR Zalutsky, DA Reardon, OR Pozzi, G Vaidyanathan, DD Bigner Nuclear medicine and biology 34 (7), 779-785, 2007 | 161 | 2007 |
| (2S)-2-(3-(1-carboxy-5-(4-211At-astatobenzamido) pentyl) ureido)-pentanedioic acid for PSMA-targeted α-particle radiopharmaceutical therapy AP Kiess, IL Minn, G Vaidyanathan, RF Hobbs, A Josefsson, C Shen, ... Journal of Nuclear Medicine 57 (10), 1569-1575, 2016 | 142 | 2016 |
| Tumor-specific anti-epidermal growth factor receptor variant III monoclonal antibodies: use of the tyramine-cellobiose radioiodination method enhances cellular retention and … CJ Reist, GE Archer, SN Kurpad, CJ Wikstrand, G Vaidyanathan, ... Cancer research 55 (19), 4375-4382, 1995 | 140 | 1995 |
| Improved synthesis of N-succinimidyl 4-[18F] fluorobenzoate and its application to the labeling of a monoclonal antibody fragment G Vaidyanathan, MR Zalutsky Bioconjugate Chemistry 5 (4), 352-356, 1994 | 136 | 1994 |
| Targeted therapy using alpha emitters G Vaidyanathan, MR Zalutsky Physics in Medicine & Biology 41 (10), 1915, 1996 | 130 | 1996 |
| Targeting breast carcinoma with radioiodinated anti-HER2 Nanobody M Pruszynski, E Koumarianou, G Vaidyanathan, H Revets, N Devoogdt, ... Nuclear medicine and biology 40 (1), 52-59, 2013 | 123 | 2013 |
| No-carrier-added synthesis of meta-[131I] iodobenzylguanidine G Vaidyanathan, MR Zalutsky Applied Radiation and Isotopes 44 (3), 621-628, 1993 | 121 | 1993 |
| Evaluation of anti-podoplanin rat monoclonal antibody NZ-1 for targeting malignant gliomas Y Kato, G Vaidyanathan, MK Kaneko, K Mishima, N Srivastava, ... Nuclear medicine and biology 37 (7), 785-794, 2010 | 111 | 2010 |
| Astatine radiopharmaceuticals: prospects and problems G Vaidyanathan, MR Zalutsky Current radiopharmaceuticals 1 (3), 177-196, 2008 | 100 | 2008 |
| Improved tumor targeting of anti-HER2 nanobody through N-succinimidyl 4-guanidinomethyl-3-iodobenzoate radiolabeling M Pruszynski, E Koumarianou, G Vaidyanathan, H Revets, N Devoogdt, ... Journal of nuclear medicine 55 (4), 650-656, 2014 | 95 | 2014 |
| 1-(meta-[211At] Astatobenzyl) guanidine: synthesis via astato demetalation and preliminary in vitro and in vivo evaluation G Vaidyanathan, MR Zalutsky Bioconjugate chemistry 3 (6), 499-503, 1992 | 91 | 1992 |
| Uptake mechanisms of meta-[123I] iodobenzylguanidine in isolated rat heart TR DeGrado, MR Zalutsky, G Vaidyanathan Nuclear medicine and biology 22 (1), 1-12, 1995 | 89 | 1995 |
| Applications of 211At and 223Ra in targeted alpha-particle radiotherapy G Vaidyanathan, M R. Zalutsky Current radiopharmaceuticals 4 (4), 283-294, 2011 | 85 | 2011 |
| Preclinical evaluation of 18F-labeled anti-HER2 nanobody conjugates for imaging HER2 receptor expression by immuno-PET G Vaidyanathan, D McDougald, J Choi, E Koumarianou, D Weitzel, ... Journal of Nuclear Medicine 57 (6), 967-973, 2016 | 83 | 2016 |
| Fluorine-18-labeled [Nle4, D-Phe7]-α-MSH, an α-melanocyte stimulating hormone analogue G Vaidyanathan, MR Zalutsky Nuclear medicine and biology 24 (2), 171-178, 1997 | 83 | 1997 |
| Astatine-211 labeled anti-HER2 5F7 single domain antibody fragment conjugates: radiolabeling and preliminary evaluation J Choi, G Vaidyanathan, E Koumarianou, CM Kang, MR Zalutsky Nuclear medicine and biology 56, 10-20, 2018 | 81 | 2018 |
